tiprankstipranks
Trending News
More News >
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (DE:2TZ)
FRANKFURT:2TZ
2TZ
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
RESEARCH TOOLSreports

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (2TZ) Stock Statistics & Valuation Metrics

Compare
0 Followers

Total Valuation

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S has a market cap or net worth of €2.42B. The enterprise value is ―.
Market Cap€2.42B
Enterprise Value

Share Statistics

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S has 200,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding200,000,000
Owned by Insiders
Owned by Institutions

Financial Efficiency

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)
Return on Assets (ROA)
Return on Invested Capital (ROIC)
Return on Capital Employed (ROCE)
Revenue Per Employee1.67M
Profits Per Employee197.17K
Employee Count4,913
Asset Turnover
Inventory Turnover

Valuation Ratios

The current PE Ratio of Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S is ―. Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s PEG ratio is ―.
PE Ratio
PS Ratio0.00
PB Ratio
Price to Fair Value
Price to FCF
Price to Operating Cash Flow
PEG Ratio

Income Statement

In the last 12 months, Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S had revenue of 8.22B and earned 986.71M in profits. Earnings per share was 1.28.
Revenue8.22B
Gross Profit3.62B
Operating Income1.10B
Pretax Income1.10B
Net Income986.71M
EBITDA1.26B
Earnings Per Share (EPS)1.28

Cash Flow

In the last 12 months, operating cash flow was 884.91M and capital expenditures 0.00, giving a free cash flow of 804.52M billion.
Operating Cash Flow884.91M
Free Cash Flow804.52M
Free Cash Flow per Share4.02

Dividends & Yields

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S pays an annual dividend of €0.155, resulting in a dividend yield of ―
Dividend Per Share€0.155
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.12
52-Week Price Change3.31%
50-Day Moving Average1.92
200-Day Moving Average2.00
Relative Strength Index (RSI)47.54
Average Volume (3m)0.00

Important Dates

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S upcoming earnings date is Aug 13, 2025, TBA Not Confirmed.
Last Earnings DateApr 29, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend DateJul 02, 2024

Financial Position

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio
Quick Ratio
Debt to Market Cap
Net Debt to EBITDA
Interest Coverage Ratio

Taxes

In the past 12 months, Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S has paid 126.66M in taxes.
Income Tax126.66M
Effective Tax Rate

Enterprise Valuation

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales
EV to EBITDA
EV to Free Cash Flow
EV to Operating Cash Flow

Balance Sheet

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S has €1.45B in cash and marketable securities with ¥252.00M in debt, giving a net cash position of -€214.05M billion.
Cash & Marketable Securities€1.45B
Total Debt¥252.00M
Net Cash-€214.05M
Net Cash Per Share-€1.07
Tangible Book Value Per Share

Margins

Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin
Operating Margin
Pretax Margin
Net Profit Margin
EBITDA Margin
EBIT Margin

Analyst Forecast

The average price target for Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart ScoreN/A
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis